Compare Freshworks Inc (FRSH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs BIO-TECHNE Corp — how do they compare? Freshworks Inc trades at $11.97 (market cap $3.31B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 3.4× Freshworks Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| FRSH | TECH | |
|---|---|---|
Market Cap | $3.31B | $11.24B |
Sector | Technology | Health |
52-Week High | $13.97 | $72.29 |
52-Week Low | $6.88 | $43.31 |
Enterprise Value | $2.68B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $11.84, up 2.16% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.17 versus $0.13 expected, and revenue growth of 16% year-over-year. Recent developments include FedRAMP 'In-Process' status for Freshservice and a leadership appointment, reinforcing its competitive position in AI-powered service operations.
The stock offers upside to the $16.50 consensus price target, driven by robust fundamentals like a 20.49% net margin and 19.7% ROE. Risks include high EV/EBITDA valuation and dependence on SaaS sector growth. Analysts are evenly split between Buy and Hold ratings, indicating cautious optimism amid execution risks.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
